Bruton's tyrosine kinase (BTK) inhibitors
- Name
- Bruton's tyrosine kinase (BTK) inhibitors
- Accession Number
- DBCAT005749
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Ibrutinib An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. Acalabrutinib A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Zanubrutinib A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. Pirtobrutinib A kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy. Orelabrutinib Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)). - Drugs & Drug Targets